Pharmaceutical Research

, 35:114 | Cite as

Tissue Distribution and Gender-Specific Protein Expression of Cytochrome P450 in five Mouse Genotypes with a Background of FVB

  • Jiamei M. Chen
  • Qisong S. Zhang
  • Xiaoyan Y. Li
  • Xia Gong
  • Yanjiao J. Ruan
  • Sijing J. Zeng
  • Linlin L. Lu
  • Xiaoxiao X. Qi
  • Ying Wang
  • Ming Hu
  • Lijun J. Zhu
  • Zhongqiu Q. Liu
Research Paper



To systematically investigate tissue distribution and gender-specific protein expression of Cytochrome P450 (Cyps) in five mouse genotypes with a background of Friend virus B (FVB).


The Cyps were extracted from the tissue S9 fractions of the main metabolic organs and then absolutely quantified by applying the UHPLC-MS/MS method.


The liver had the highest expression of Cyps, followed by the small intestine and kidney. In the liver, Cyp1a2, Cyp2c29, Cyp2c39, Cyp2d22, Cyp2e1, and Cyp3a11 were the main isoforms. Cyp1a2 and Cyp2c29 were male-specific, while Cyp2c39 was female-specific. Compared with the expression in Wild-type (WT) FVB mice, the expression of Cyp1a2, Cyp1b1, Cyp2d22, and Cyp3a25 significantly decreased in female efflux transporter (ET) knockout mice. In the small intestine, Cyp2c29 and Cyp3a11 were the major isoforms. Knockout of ET didn’t alter the expression levels of most Cyps. However, female ET knockout mice presented higher Cyp2c29 expression than WT FVB mice. The Cyp7a1 expression was markedly decreased in ET knockout mice except Bcrp1−/− mice. In the kidney, Cyp2e1 was the main isoform and exhibited male specificity. Knockout of ET slightly affected the protein expression of Cyps in the brain, heart, lung, spleen and stomach.


A comprehensive understanding of the distribution characteristics and gender-specific expression of Cyps in major metabolic organs of WT and ET knockout FVB mice should contribute to a better understanding of drug efficacy and toxicity, and drug-drug interactions.

Key words

cytochrome P450 efflux transporter gender-specific knockout tissue distribution 



Cytochrome P450


Efflux transporter


Friend virus B




Author Contributions

Participated in research design: Chen, Hu, and Liu.

Conducted experiments: Chen, Li, and Zeng.

Contributed new reagents or analytic tools: Gong, Ruan, Lu, Qi, Wang, and Hu.

Performed data analysis: Chen, Zhang, Zhu, and Liu.

Wrote or contributed to the writing of the manuscript: Chen, Zhang, Zhu, Hu, and Liu.

Supplementary material

11095_2018_2389_MOESM1_ESM.docx (31 kb)
ESM 1 (DOCX 31 kb)


  1. 1.
    Seibert C, Davidson BR, Fuller BJ, Patterson LH, Griffiths WJ, Wang Y. Multiple-approaches to the identification and quantification of cytochromes P450 in human liver tissue by mass spectrometry. J Proteome Res. 2009;8:1672–81.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Dingand X, Kaminsky LS. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol. 2003;43:149.CrossRefGoogle Scholar
  3. 3.
    Tsunedomi R, Hazama S, Okayama N, Oka M, Nagano H. Rapid and sensitive detection of UGT1A1 polymorphisms associated with irinotecan toxicity by a novel DNA microarray. Cancer Sci. 2017;108:1504–9.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Longo UG, Forriol F, Campi S, Maffulli N, Denaro V. Animal models for translational research on shoulder pathologies: from bench to bedside. Sports Med Arthrosc Rev. 2011;19:184–93.CrossRefPubMedGoogle Scholar
  5. 5.
    Yang Z, Zhu W, Gao S, Yin T, Jiang W, Breast MH. Cancer resistance protein (ABCG2) determines distribution of genistein phase II metabolites: reevaluation of the roles of ABCG2 in the disposition of genistein. Drug Metab Dispos: The Biol Fate Chem. 2012;40:1883–93.CrossRefGoogle Scholar
  6. 6.
    Agarwal S, Sane R, Gallardo JL, Ohlfest JR, Elmquist WF. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmacol Exp Ther. 2010;334:147–55.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Agarwal S, Uchida Y, Mittapalli RK, Sane R, Terasaki T, Elmquist WF. Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice. Drug Metab Dispos Biol Fate Chem. 2012;40:1164–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Grube M, Reuther S, Meyer ZSH, Köck K, Draber K, Ritter CA, et al. Organic anion transporting polypeptide 2B1 and breast cancer resistance protein interact in the transepithelial transport of steroid sulfates in human placenta. Drug Metab Dispos: The Biol Fate Chem. 2007;35:30.CrossRefGoogle Scholar
  9. 9.
    Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2009;48:143–57.CrossRefGoogle Scholar
  10. 10.
    Franconi F, Brunelleschi S, Steardo L, Cuomo V. Gender differences in drug responses. Pharmacol Res. 2007;55:81–95.CrossRefPubMedGoogle Scholar
  11. 11.
    Wolbold R, Klein K, Burk O, Nüssler AK, Neuhaus P, Eichelbaum M, et al. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology. 2003;38:978–88.CrossRefPubMedGoogle Scholar
  12. 12.
    Rodríguezantona C, Donato MT, Pareja E, Gómezlechón MJ, Castell JV. Cytochrome P-450 mRNA expression in human liver and its relationship with enzyme activity. Arch Biochem Biophys. 2001;393:308–15.CrossRefGoogle Scholar
  13. 13.
    Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. The human intestinal cytochrome p450 “pie”. Drug Metab Dispos. 2006;34:880–6.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Liu ZQ, Chen J, Zheng H, Zeng S, Xie C, Yan L, et al. Profiles and gender-specific of UDP-glucuronosyltransferases and sulfotransferases expressions in the major metabolic organs of wild-type and efflux transporter knockout FVB mice. Mol Pharm. 2017;14:2967.CrossRefPubMedGoogle Scholar
  15. 15.
    Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, et al. Drug-drug interactions for udp-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (auci/auc) ratios. Drug Metab Dispos Biol Fate Chem. 2004;32:1201.CrossRefPubMedGoogle Scholar
  16. 16.
    Chen J, Zhu L, Li X, Zheng H, Yan T, Xie C, et al. High Throughput and Reliable Isotope Label-free approach for Profiling 24 Metabolic Enzymes in FVB Mice and Gender Differences. Drug Metab Dispos Biol Fate Chem. 2017;45:624.CrossRefPubMedGoogle Scholar
  17. 17.
    Dai D, Bai R, Hodgson E, Rose RL. Cloning, sequencing, heterologous expression, and characterization of murine cytochrome P450 3a25*(Cyp3a25), a testosterone 6beta-hydroxylase. J Biochem Mol Toxicol. 2001;15:90–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Matsunaga T, Tanaka H, Higuchi S, Shibayama K, Kishi N, Watanabe K, et al. Oxidation mechanism of 7-hydroxy-delta 8-tetrahydrocannabinol and 8-hydroxy-delta 9-tetrahydrocannabinol to the corresponding ketones by CYP3A11. Drug Metab Dispos Biol Fate Chem. 2001;29:1485.PubMedGoogle Scholar
  19. 19.
    Hagemeyer CE, Rosenbrock H, Ditter M, Knoth R, Volk B. Predominantly neuronal expression of cytochrome P450 isoforms CYP3A11 and CYP3A13 in mouse brain. Neuroscience. 2003;117:521–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Martignoni M, Groothuis G, De KR. Comparison of mouse and rat cytochrome P450-mediated metabolism in liver and intestine. Drug Metab Dispos. 2006;34:1047.PubMedGoogle Scholar
  21. 21.
    Down MJ, Arkle S, Mills JJ. Regulation and induction of CYP3A11, CYP3A13 and CYP3A25 in C57BL/6J mouse liver. Arch Biochem Biophys. 2007;457:105–10.CrossRefPubMedGoogle Scholar
  22. 22.
    Dianimoore S, Papachristou F, Labitzke E, Rifkind AB. Induction of CYP1A and cyp2-mediated arachidonic acid epoxygenation and suppression of 20-hydroxyeicosatetraenoic acid by imidazole derivatives including the aromatase inhibitor vorozole. Drug Metab Dispos Biol Fate Chem. 2006;34:1376.CrossRefGoogle Scholar
  23. 23.
    Van RA, Välitalo PA, Peeters MY, Boerma D, Huisman FW, Van RB, et al. Morbidly obese patients exhibit increased CYP2E1-mediated oxidation of acetaminophen. Clin Pharmacokinet. 2016;55:833–47.CrossRefGoogle Scholar
  24. 24.
    Graves JP, Gruzdev A, Bradbury JA, Degraff LM, Edin ML, Zeldin DC. Characterization of the Tissue Distribution of the Mouse Cyp2c Subfamily by Quantitative PCR Analysis. Drug Metab Dispos. 2017;45:807–16.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Blume N, Leonard J, Xu ZJ, Watanabe O, Remotti H, Fishman J. Characterization of Cyp2d22, a novel cytochrome P450 expressed in mouse mammary cells. Arch Biochem Biophys. 2000;381:191–204.CrossRefPubMedGoogle Scholar
  26. 26.
    Joshiand M, Tyndale RF. Regional and cellular distribution of CYP2E1 in monkey brain and its induction by chronic nicotine. Neuropharmacology. 2006;50:568–75.CrossRefGoogle Scholar
  27. 27.
    Jarukamjorn K, Sakuma T, Jaruchotikamol A, Ishino Y, Oguro M, Nemoto N. Modified expression of cytochrome P450 mRNAs by growth hormone in mouse liver. Toxicology. 2006;219:97–105.CrossRefPubMedGoogle Scholar
  28. 28.
    Löfgren S, Baldwin RM, Carlerös M, Terelius Y, Franssonsteen R, Mwinyi J, et al. Regulation of human CYP2C18 and CYP2C19 in transgenic mice: influence of castration, testosterone, and growth hormone. Drug Metab Dispos Biol Fate Chem. 2009;37:1505.CrossRefPubMedGoogle Scholar
  29. 29.
    Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics? Clin Pharmacokinet. 2002;41:329–42.CrossRefPubMedGoogle Scholar
  30. 30.
    Shimada T. Inhibition of carcinogen-activating cytochrome P450 enzymes by xenobiotic Chemicals in Relation to Antimutagenicity and Anticarcinogenicity. Toxicological Research. 2017;33:79–96.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Nebert DW, Shi Z, Gálvezperalta M, Uno S, Dragin N. Oral benzo[a]pyrene: understanding pharmacokinetics, detoxication, and consequences--Cyp1 knockout mouse lines as a paradigm. Mol Pharmacol. 2013;84:304–13.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Diliberto JJ, Akubue PI, Luebke RW, Birnbaum LS. Dose-response relationships of tissue distribution and induction of CYP1A1 and CYP1A2 enzymatic activities following acute exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in mice. Toxicol Appl Pharmacol. 1995;130:197–208.CrossRefPubMedGoogle Scholar
  33. 33.
    Kathrin K, Stefan W, Miia T, Matthias S, Zanger UM. Pathway-targeted pharmacogenomics of CYP1A2 in human liver. Front Pharmacol. 2010;1:129.Google Scholar
  34. 34.
    Kim H, Reddy S, Novak RF. 3-Methylcholanthrene and pyridine effects on CYP1A1 and CYP1A2 expression in rat renal tissue. Drug Metab Dispos Biol Fate Chem. 1995;23:818.PubMedGoogle Scholar
  35. 35.
    Nagai K, Fukuno S, Suzuki H, Konishi H. Higher gene expression of CYP1A2, 2B1 and 2D2 in the brain of female compared with male rats. Die Pharmazie. 2016;71:334–6.PubMedGoogle Scholar
  36. 36.
    Hodgson DYRE. Constitutive expression and induction of CYP1B1 mRNA in the mouse. J Biochem Mol Toxicol. 1999;13:249–51.CrossRefPubMedGoogle Scholar
  37. 37.
    Messina A, Siniscalco A, Puccinelli E, Gervasi PG, Longo V. Cloning and tissues expression of the pig CYP1B1 and CYP2J34. Res Vet Sci. 2012;92:438–43.CrossRefPubMedGoogle Scholar
  38. 38.
    Lan X, Yan J, Ren J, Zhong B, Li J, Li Y, et al. A novel long noncoding RNA Lnc-HC binds hnRNPA2B1 to regulate expressions of Cyp7a1 and Abca1 in hepatocytic cholesterol metabolism. Hepatology. 2016;64:58–72.CrossRefPubMedGoogle Scholar
  39. 39.
    Erickson SK, Lear SR, Deane S, Dubrac S, Huling SL, Nguyen L, et al. Hypercholesterolemia and changes in lipid and bile acid metabolism in male and female cyp7A1-deficient mice. J Lipid Res. 2003;44:1001–9.CrossRefPubMedGoogle Scholar
  40. 40.
    Wu Z, Martin KO, Javitt NB, Chiang JYL. Structure and functions of human oxysterol 7α-hydroxylase cDNAs and gene CYP7B1. J Lipid Res. 1999;40:2195.PubMedGoogle Scholar
  41. 41.
    Kumagai Y, Sekimoto M, Okamoto M, Kurita R, Kojima M, Degawa M. Involvement of hepatic IL-1 in the strain-dependent sex differences in serum total cholesterol levels in rats. Biol Pharm Bull. 2014;37:654–8.CrossRefPubMedGoogle Scholar
  42. 42.
    Li T, Chen W, Chiang JY. PXR induces CYP27A1 and regulates cholesterol metabolism in the intestine. J Lipid Res. 2007;48:373–84.CrossRefPubMedGoogle Scholar
  43. 43.
    Tieu EW, Li W, Chen J, Baldisseri DM, Slominski AT, Tuckey RC. Metabolism of cholesterol, vitamin D3 and 20-hydroxyvitamin D3 incorporated into phospholipid vesicles by human CYP27A1. J Steroid Biochem Mol Biol. 2012;129:163–71.CrossRefPubMedGoogle Scholar
  44. 44.
    Uno Y, Hosaka S, Yamazaki H. Identification and analysis of CYP7A1, CYP17A1, CYP20A1, CYP27A1 and CYP51A1 in Cynomolgus macaques. J Vet Med Sci. 2014;76:1647–50.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Jiamei M. Chen
    • 1
  • Qisong S. Zhang
    • 1
  • Xiaoyan Y. Li
    • 1
  • Xia Gong
    • 1
  • Yanjiao J. Ruan
    • 1
  • Sijing J. Zeng
    • 1
  • Linlin L. Lu
    • 1
  • Xiaoxiao X. Qi
    • 1
  • Ying Wang
    • 1
  • Ming Hu
    • 2
  • Lijun J. Zhu
    • 1
  • Zhongqiu Q. Liu
    • 1
    • 3
  1. 1.International Institute for Translational Chinese MedicineGuangzhou University of Chinese MedicineGuangzhouPeople’s Republic of China
  2. 2.Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy,University of HoustonHoustonUSA
  3. 3.State Key Laboratory of Quality Research in Chinese MedicineMacau University of Science and TechnologyMacauChina

Personalised recommendations